PMID- 28267084
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181110
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 39
IP  - 5
DP  - 2017 Jul
TI  - Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and 
      a Noninvasive Biomarker of Liver Fibrosis Associated With Transient 
      Myeloproliferative Disorder in Down Syndrome.
PG  - e285-e289
LID - 10.1097/MPH.0000000000000809 [doi]
AB  - Liver fibrosis is one of the common complications of transient myeloproliferative 
      disorder (TMD) in Down syndrome (DS), but the exact molecular pathogenesis is 
      largely unknown. We herein report a neonate of DS with liver fibrosis associated 
      with TMD, in which we performed the serial profibrogenic cytokines analyses. We 
      found the active monocyte chemoattractant protein-1 expression in the affected 
      liver tissue and also found that both serum and urinary monocyte chemoattractant 
      protein-1 concentrations are noninvasive biomarkers of liver fibrosis. We also 
      showed a prospective of the future anticytokine therapy with herbal medicine for 
      the liver fibrosis associated with TMD in DS.
FAU - Kobayashi, Kenichiro
AU  - Kobayashi K
AD  - Departments of *Pediatrics  paragraph signPediatric Surgery #Diagnostic Pathology, Hyogo 
      Prefectural Amagasaki General Medical Center, Hyogo Departments of daggerPediatric 
      Hematology and Oncology Research double daggerPathology, National Research Institute for 
      Child Health and Development, Tokyo  section signDepartment of Pathology and Laboratory 
      Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba  parallelDepartment of 
      Pathology, Tokai University School of Medicine, Kanagawa, Japan.
FAU - Yoshioka, Takako
AU  - Yoshioka T
FAU - Miyauchi, Jun
AU  - Miyauchi J
FAU - Nakazawa, Atsuko
AU  - Nakazawa A
FAU - Yamazaki, Shigeaki
AU  - Yamazaki S
FAU - Ono, Hiromi
AU  - Ono H
FAU - Tatsuno, Michiko
AU  - Tatsuno M
FAU - Iijima, Kenta
AU  - Iijima K
FAU - Takahashi, Chiaki
AU  - Takahashi C
FAU - Okada, Yoko
AU  - Okada Y
FAU - Teranishi, Kenji
AU  - Teranishi K
FAU - Matsunaga, Takaaki
AU  - Matsunaga T
FAU - Matsushima, Chieko
AU  - Matsushima C
FAU - Inagaki, Mayo
AU  - Inagaki M
FAU - Suehiro, Minoru
AU  - Suehiro M
FAU - Suehiro, Saori
AU  - Suehiro S
FAU - Nishitani, Masahiko
AU  - Nishitani M
FAU - Kubota, Hirohito
AU  - Kubota H
FAU - Iio, Jun
AU  - Iio J
FAU - Nishida, Yoshinobu
AU  - Nishida Y
FAU - Katayama, Tetsuo
AU  - Katayama T
FAU - Takada, Narito
AU  - Takada N
FAU - Watanabe, Kentaro
AU  - Watanabe K
FAU - Yamamoto, Tetsuro
AU  - Yamamoto T
FAU - Yasumizu, Ryoji
AU  - Yasumizu R
FAU - Matsuoka, Kentaro
AU  - Matsuoka K
FAU - Ohki, Kentaro
AU  - Ohki K
FAU - Kiyokawa, Nobutaka
AU  - Kiyokawa N
FAU - Maihara, Toshiro
AU  - Maihara T
FAU - Usami, Ikuya
AU  - Usami I
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - Myeloproliferative Syndrome, Transient
SB  - IM
MH  - Biomarkers
MH  - Chemokine CCL2/*analysis
MH  - Cytokines/analysis
MH  - Diagnosis, Differential
MH  - Down Syndrome/*complications
MH  - Humans
MH  - Infant, Newborn
MH  - Leukemoid Reaction/*complications
MH  - Liver/chemistry/pathology
MH  - Liver Cirrhosis/*diagnosis/etiology
EDAT- 2017/03/08 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/03/08 06:00
PHST- 2017/03/08 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/03/08 06:00 [entrez]
AID - 10.1097/MPH.0000000000000809 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2017 Jul;39(5):e285-e289. doi: 
      10.1097/MPH.0000000000000809.